Lv4
520 积分 2022-11-14 加入
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer
7天前
已完结
Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care
22天前
已完结
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer
25天前
已完结
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
27天前
已完结
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
27天前
已完结
Personalized intensification of treatment for hormone-sensitive prostate cancer
1个月前
已完结
P150 Updated Overall Survival (OS) estimates leveraging long term extension data from TITAN study evaluating Apalutamide (APA) versus Placebo (PBO) in metastatic Hormone Sensitive Prostate Cancer (mHSPC) patients
2个月前
已完结
Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer
2个月前
已完结
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2个月前
已完结
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial
2个月前
已完结
皖公网安备34019202002308
